Skip to main content

Advertisement

SpringerLink
Log in

EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry

  • Laboratory Investigation
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Development of novel patient stratification tools for cancer is a challenge that require advanced molecular screening and a detailed understanding of tumour signalling networks. Here, we apply phospho-specific flow cytometry for signal profiling of primary glioblastoma tumours after preservation of single-cell phosphorylation status as a strategy for evaluation of tumour signalling potential and assessment of rapamycin-mediated mTOR inhibition. The method has already enhanced insight into cancers and disorders of the immune system, and our study demonstrate a great potential to improve the understanding of aberrant signalling in glioblastoma and other solid tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Akhavan D, Cloughesy TF, Mischel PS (2010) mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol 12:882–889

    Article  PubMed  CAS  Google Scholar 

  2. Benito R, Gil-Benso R, Quilis V, Perez M, Gregori-Romero M, Roldan P, Gonzalez-Darder J, Cerda-Nicolas M, Lopez-Gines C (2010) Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features. Neuropathology 30:392–400

    Article  PubMed  Google Scholar 

  3. Chalhoub N, Baker SJ (2009) PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4:127–150

    Article  PubMed  CAS  Google Scholar 

  4. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS (2003) Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742–2746

    PubMed  CAS  Google Scholar 

  5. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8

    Article  PubMed  Google Scholar 

  6. Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP, James CD (1994) Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9:2313–2320

    PubMed  CAS  Google Scholar 

  7. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK (2007) Malignant astrocytic glioma: genetics, biology and paths to treatment. Genes Dev 21:2683–2710

    Article  PubMed  CAS  Google Scholar 

  8. Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SK, Oba-Shinjo SM, Carlotti CG, Caballero OL, Simpson AJ, Brock MV, Massion PP, Carson BS, Riggins GJ (2006) PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 4:709–714

    Article  PubMed  CAS  Google Scholar 

  9. Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2:e24

    Article  Google Scholar 

  10. Kanu OO, Mehta A, Di C, Lin N, Bortoff K, Bigner DD, Yan H, Adamson DC (2009) Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 13:701–718

    Article  PubMed  CAS  Google Scholar 

  11. Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E, Abrey LE (2009) A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 92:99–105

    Article  PubMed  CAS  Google Scholar 

  12. Krutzik PO, Clutter MR, Trejo A, Nolan GP (2011) Fluorescent cell barcoding for multiplex flow cytometry. Curr Protoc Cytom. doi:10.1002/0471142956.cy0631s55

  13. Krutzik PO, Nolan GP (2006) Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods 3:361–368

    Article  PubMed  CAS  Google Scholar 

  14. Lurje G, Lenz HJ (2009) EGFR signaling and drug discovery. Oncology 77:400–410

    Article  PubMed  CAS  Google Scholar 

  15. Masui K, Cloughesy TF, Mischel PS (2012) Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 38:271–291

    Article  PubMed  CAS  Google Scholar 

  16. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024

    Article  PubMed  CAS  Google Scholar 

  17. Merlo V, Longo M, Novello S, Scagliotti GV (2011) EGFR pathway in advanced non-small cell lung cancer. Front Biosci (Schol Ed) 3:501–517

    Article  Google Scholar 

  18. Miller TW, Rexer BN, Garrett JT, Arteaga CL (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13:224

    Article  PubMed  CAS  Google Scholar 

  19. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF (2003) Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22:2361–2373

    Article  PubMed  CAS  Google Scholar 

  20. Ogino S, Galon J, Fuchs CS, Dranoff G (2011) Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 8:711–719

    Article  PubMed  CAS  Google Scholar 

  21. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC, Thomas G (2004) S6K1(−/−)/S6K2(−/−) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24:3112–3124

    Article  PubMed  CAS  Google Scholar 

  22. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L, Parsons R (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten ± mice. Proc Natl Acad Sci USA 98:10320–10325

    Article  PubMed  CAS  Google Scholar 

  23. Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, Weller M, Stupp R (2011) Current concepts and management of glioblastoma. Ann Neurol 70:9–21

    Article  PubMed  Google Scholar 

  24. Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, Lichtenstein A (2002) Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62:5027–5034

    PubMed  CAS  Google Scholar 

  25. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  26. Sugawa N, Ekstrand AJ, James CD, Collins VP (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87:8602–8606

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors wish to thank Jorun Solheim for work on sequencing of the tumour samples. The work was supported by grants from the Norwegian Cancer Society, South-Eastern Regional Health Authority and the Research Council of Norway.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Author notes

  1. Isabelle Cornez

    Present address: Biomedizinisches Zentrum (BMZ), Medizinische Klinik III, 53127, Bonn, Germany

Authors and Affiliations

  1. The Biotechnology Centre of Oslo and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo, Gaustadalléen 21, 0349, Oslo, Norway

    Isabelle Cornez, Kjetil Taskén & Torunn Berge

  2. Vilhelm Magnus Laboratory for Neurosurgical Research, Institute for Surgical Research, Oslo University Hospital, Oslo, Norway

    Mrinal Joel & Iver A. Langmoen

  3. Department of Physiology, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway

    Mrinal Joel & Joel C. Glover

  4. Norwegian Center for Stem Cell Research, Oslo, Norway

    Mrinal Joel, Iver A. Langmoen & Joel C. Glover

  5. Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway

    Kjetil Taskén

  6. Department of Neurosurgery, Oslo University Hospital, Oslo, Norway

    Iver A. Langmoen

Authors
  1. Isabelle Cornez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mrinal Joel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kjetil Taskén
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Iver A. Langmoen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joel C. Glover
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Torunn Berge
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Torunn Berge.

Additional information

Isabelle Cornez and Mrinal Joel contributed equally to the study.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 804 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cornez, I., Joel, M., Taskén, K. et al. EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry. J Neurooncol 112, 49–57 (2013). https://doi.org/10.1007/s11060-012-1035-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-012-1035-9

Keywords

Search

Navigation